Alzex Neuropharma

Alzex Neuropharma Current Assets

Current Assets of Alzex Neuropharma (TRRI) as of Oct 17, 2026.

Current Assets

0.00USD

Last updated:

Current Assets of Alzex Neuropharma is 2013 0.00 USD. Current Assets of Alzex Neuropharma was 2012 0.00 USD. It decreases by % lower compared to the previous year.

The Alzex Neuropharma Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2011
2,400.00 USD
Jan 1, 2012
0.00 USD
Jan 1, 2013
0.00 USD
The Alzex Neuropharma Current Assets history
YEARCurrent AssetsYoY
0.00USD—
0.00USD-100.00%
2,400.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Alzex Neuropharma Stock analysis

What does Alzex Neuropharma do? Alzex Neuropharma Inc, with ticker TRRI and ISIN US89656L1035, is a company based in Henderson, United States. It operates within the Materials sector, specifically in the Metals & Mining industry. The company went public on July 11, 2001. Its website is https://trinresinc.com/. According to the provided information, Alzex Neuropharma Inc engages in the exploration and development of natural resource interests. The company is headquartered in Henderson, Nevada. It is involved in research and development focused on treatments for brain diseases. The firm is also developing new drugs for the symptomatic treatment of Alzheimer’s Disease, leveraging a platform technology that may have applications for other neurological conditions. The company's activities include chemical development of its drug candidates. The information provided does not specify any founding year, key personnel, acquisitions, or detailed financial figures. The company's primary focus appears to be on neurological disease treatments, particularly Alzheimer’s, through its research and development efforts. Alzex Neuropharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alzex Neuropharma stock

On Eulerpool you can find the complete historical development of Current Assets Alzex Neuropharma since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Alzex Neuropharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Alzex Neuropharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Alzex Neuropharma